Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Consolidated Net Income: 2019-2025

Historic Consolidated Net Income for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to -$7.3 million.

  • Keros Therapeutics' Consolidated Net Income rose 86.25% to -$7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.4 million, marking a year-over-year increase of 134.32%. This contributed to the annual value of -$187.4 million for FY2024, which is 22.46% down from last year.
  • As of Q3 2025, Keros Therapeutics' Consolidated Net Income stood at -$7.3 million, which was up 76.28% from -$30.7 million recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Consolidated Net Income registered a high of $148.5 million during Q1 2025, and its lowest value of -$53.0 million during Q3 2024.
  • Moreover, its 3-year median value for Consolidated Net Income was -$43.1 million (2024), whereas its average is -$22.4 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first slumped by 328.21% in 2022, then soared by 444.32% in 2025.
  • Quarterly analysis of 5 years shows Keros Therapeutics' Consolidated Net Income stood at -$6.9 million in 2021, then tumbled by 328.21% to -$29.7 million in 2022, then plummeted by 56.32% to -$46.5 million in 2023, then rose by 0.92% to -$46.0 million in 2024, then surged by 86.25% to -$7.3 million in 2025.
  • Its Consolidated Net Income stands at -$7.3 million for Q3 2025, versus -$30.7 million for Q2 2025 and $148.5 million for Q1 2025.